2
Clinical Trials associated with Anti-CD19 CAR-T cell therapeutics (Shanghai Unicar-Therapy Bio-medicine Technology)CD19 Chimeric Antigen Receptors and CD19 Positive Feeder T Cells as a Leukemia Consolidation Treatment
This is a single center,randomized ,two-cohorts, open-label ,phase 1/2 study to evaluate the efficacy and safety of T cells expressing CD19 chimeric antigen receptors combined with CD19 positive feeder T cells treatment for CD19+ acute lymphoblastic leukemia patients in remission .
CAR-T Therapy for Central Nervous System B-cell Acute Lymphocytic Leukemia
This study will evaluates the safety and efficacy of Chimeric antigen receptor T cells (CAR-T) in treating central nervous system B-cell acute lymphocytic leukemia.
100 Clinical Results associated with Anti-CD19 CAR-T cell therapeutics (Shanghai Unicar-Therapy Bio-medicine Technology)
100 Translational Medicine associated with Anti-CD19 CAR-T cell therapeutics (Shanghai Unicar-Therapy Bio-medicine Technology)
100 Patents (Medical) associated with Anti-CD19 CAR-T cell therapeutics (Shanghai Unicar-Therapy Bio-medicine Technology)
100 Deals associated with Anti-CD19 CAR-T cell therapeutics (Shanghai Unicar-Therapy Bio-medicine Technology)